Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Angion Biomedica

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jul 26, 2022

Nasdaq Down 100 Points; Angion Biomedica Shares Plummet

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday.

Benzinga · Jun 30, 2022

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jun 30, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why

Angion Biomedica Corp (NASDAQ:ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy. The trial began enrolling patients in December 2021. A reassessment was conducted following a potential safety signal of an unexpected and substantial…

Benzinga · Jun 30, 2022

Angion Biomedica's Return On Capital Employed Overview

Benzinga Pro data, Angion Biomedica (NASDAQ:ANGN) reported Q1 sales of $1.65 million. Earnings fell to a loss of $14.24 million, resulting in a 195.63% decrease from last quarter.

Benzinga · Jun 22, 2022

Angion Biomedica: Q1 Earnings Insights

Angion Biomedica (NASDAQ:ANGN) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga · May 16, 2022

Angion Biomedica's Return On Capital Employed Insights

According to Benzinga Pro, during Q4, Angion Biomedica (NASDAQ:ANGN) earned $14.89 million, a 194.82% increase from the preceding quarter. Angion Biomedica also posted a total of $25.94 million in sales, a 1676.78% increase since Q3.

Benzinga · Mar 31, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

425,006 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.